Brief: Island Pharmaceuticals Receives IRB Approval For ISLA-101 Phase 2A Peach 1 Clinical Trial
15/12/2022 01:32
Dec 15 (Reuters) - Island Pharmaceuticals Ltd ILA.AX :
* INSTITUTIONAL REVIEW BOARD APPROVAL GRANTED FOR ISLA-101
PHASE
2A PEACH 1 CLINICAL TRIAL
Source text for Eikon: ID:nASX9k4GQM
Further company coverage: ILA.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic